Quotidiano Nazionale logo
quotidiano nazionale
10 gen 2022
10 gen 2022

Omicron, vaccino Pfizer pronto a marzo. Ema valuta la pillola

L'Agenzia Ue: risultato nelle prossime settimane

10 gen 2022
An undated handout photo made available by Pfizer Inc. shows Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, being manufactured in Freiburg, Germany (issued 15 December 2021). US pharmaceutical company Pfizer Inc. announced on 14 December 2021, final results from an analysis on high-risk patients of its phase 2/3 EPIC-HR study of its novel COVID-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) confirming the drug's efficacy. According to a news release, the pill, which showed close to 90 percent efficacy in preventing hospitalisation or death compared to placebo, is said to retain robust antiviral activity against variants of concern (VoC) as well as other coronaviruses. ANSA/PFIZER INC. HANDOUT -- MANDATORY CREDIT-- HANDOUT EDITORIAL USE ONLY/NO SALES
La produzione della pillola Paxlovid di Pfizer
An undated handout photo made available by Pfizer Inc. shows Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, being manufactured in Freiburg, Germany (issued 15 December 2021). US pharmaceutical company Pfizer Inc. announced on 14 December 2021, final results from an analysis on high-risk patients of its phase 2/3 EPIC-HR study of its novel COVID-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) confirming the drug's efficacy. According to a news release, the pill, which showed close to 90 percent efficacy in preventing hospitalisation or death compared to placebo, is said to retain robust antiviral activity against variants of concern (VoC) as well as other coronaviruses. ANSA/PFIZER INC. HANDOUT -- MANDATORY CREDIT-- HANDOUT EDITORIAL USE ONLY/NO SALES
La produzione della pillola Paxlovid di Pfizer

© Riproduzione riservata

Iscriviti alla newsletter.

Il modo più facile per rimanere sempre aggiornati

Hai già un account?